Evidence map›Paper›PMID 31657690›Full record

ReviewCurrent diabetes reviews2020

Type 2 Diabetes and its Impact on the Immune System.

Afiat Berbudi, Nofri Rahmadika, Adi Imam Tjahjadi, Rovina Ruslami

Open access · greenAbstract readReview
In one paragraph

Review in Current diabetes reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 760 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
760citing papers in PubMed, 12 pooled it
59.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

760 citing papers in PubMed, 12 syntheses or guidelines pooled it, 1,113 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Article
  14. Article
  15. Article
  16. Diabetic Autonomic Neuropathy and Impaired Inflammatory Reflex.Endocrinology, diabetes & metabolism · 2026
    Review
  17. Article
  18. Review
  19. Article
  20. Article

700 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Afiat BerbudiDepartment of Biomedical Sciences, Parasitology Division, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Nofri RahmadikaInfectious Disease Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Adi Imam TjahjadiInfectious Disease Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Rovina RuslamiInfectious Disease Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Padjadjaran University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionType 2 Diabetes (T2D) is a major health problem worldwide. This metabolic disease is indicated by high blood glucose levels due to insufficient insulin production by the pancreas. An inflammatory response occurs as a result of the immune response to high blood glucose levels as well as the presence of inflammatory mediators produced by adipocytes and macrophages in fat tissue. This low and chronic inflammation damages the pancreatic beta cells and leads to insufficient insulin production, which results in hyperglycemia. Hyperglycemia in diabetes is thought to cause dysfunction of the immune response, which fails to control the spread of invading pathogens in diabetic subjects. Therefore, diabetic subjects are known to more susceptible to infections. The increased prevalence of T2D will increase the incidence of infectious diseases and related comorbidities.

objectiveThis review provides an overview of the immunological aspect of T2D and the possible mechanisms that result in increased infections in diabetics.

conclusionA better understanding of how immune dysfunctions occur during hyperglycemia can lead to novel treatments and preventions for infectious diseases and T2D comorbidities, thus improving the outcome of infectious disease treatment in T2D patients.

Indexed as

Chronic DiseaseDiabetes Mellitus, Type 2HumansHyperglycemiaImmune SystemInfectionsInflammationInsulinInsulin-Secreting CellsInsulincomorbidityhyperglycemiaimmune dysfunctioninfectiontreatment outcome.Type 2 diabetes

Identifiers

PMID31657690
PMCPMC7475801
OpenAlexW2982433977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.